Phase II Trial of RAD001 in Refractory Colorectal Cancer

ABSTRACT: Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2029789 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR